News articles about Dare Bioscience (NASDAQ:DARE) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dare Bioscience earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.3954255957962 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Separately, ValuEngine upgraded Dare Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th.
Dare Bioscience (DARE) traded up $0.03 on Friday, hitting $2.40. The stock had a trading volume of 36,300 shares, compared to its average volume of 30,133. Dare Bioscience has a 52 week low of $2.11 and a 52 week high of $35.80.
TRADEMARK VIOLATION NOTICE: This article was first reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://transcriptdaily.com/2018/01/05/dare-bioscience-dare-receiving-somewhat-favorable-news-coverage-study-finds.html.
About Dare Bioscience
Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.